MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial

Reporter: Annemarie Fernandes
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 3 de junio del 2012

Translation for this article does not exist

Blogs

Eight Tips for Addressing Medical Billing Issues
by Christina Bach, MSW, LCSW, OSW-C
May 25, 2016